News with Multimedia
-
Le test sanguin Shield™ de Guardant Health est approuvé par la FDA en tant qu’option de dépistage primaire, ouvrant la voie au remboursement par Medicare et à une nouvelle ère de dépistage du cancer colorectal
07/30/2024 - 01:37 AM
-
Samenvatting: Cepton ondertekent definitief akkoord om overgenomen te worden door Koito
07/30/2024 - 12:31 AM
-
Riassunto: Cepton firma un accordo definitivo per essere rilevata da Koito
07/30/2024 - 12:05 AM
-
Cepton签署被Koito收购的最终协议
07/29/2024 - 11:55 PM
-
Cepton簽署被Koito收購的最終協議
07/29/2024 - 11:55 PM
-
Cepton assina acordo definitivo para ser adquirida pela Koito
07/29/2024 - 11:42 PM
-
Cepton unterzeichnet endgültige Vereinbarung zur Übernahme durch Koito
07/29/2024 - 10:54 PM
-
Cepton signe un accord définitif en vue de son acquisition par Koito
07/29/2024 - 10:39 PM
-
Infogain Appoints Mohit Bhat as Chief Delivery & Innovation Officer
07/29/2024 - 10:00 PM
-
Gora Kadan Earns a Three Key Rating in the Inaugural Michelin Key List for Asia
07/29/2024 - 10:00 PM
-
Cepton firma un acuerdo definitivo para ser adquirida por Koito
07/29/2024 - 09:45 PM
-
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
07/29/2024 - 08:00 PM
-
Magnachip Expands Solar Energy Power Product Lineup with the Release of 1200V IGBT in TO-247PLUS Package
07/29/2024 - 06:55 PM
-
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
07/29/2024 - 06:30 PM
-
Japanese Medtech Startup, CoreTissue BioEngineering, Becomes First Company Accepted Into Accelerator Program Backed by Mitsubishi Corporation (Americas) and Fogarty Innovation
07/29/2024 - 06:00 PM